1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited

CLVLF
Clinuvel Pharmaceuticals LimitedUS flagOther OTC
6.40
USD
- -
- -
322.63MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.04
0.06
0.07
0.14
0.35
0.53
0.64
0.66
0.97
1.33
1.59
1.77
1.9
Basic EPS, GAAP
-0.19
-0.14
-0.24
-0.07
0.15
0.28
0.38
0.34
0.5
0.42
0.62
0.72
0.72
Free Cash Flow per Basic Share
-0.2
-0.12
-0.1
-0.11
0.21
- -
-0.01
-0.02
-0.02
-0.01
-0.02
-0.11
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
0.02
0.02
0.03
0.03
0.04
0.05
0.05
Book Value per Share
0.36
0.36
0.2
0.3
0.47
0.75
1.16
1.46
1.9
2.3
2.88
3.99
4.65
Tangible Book Value per Share
0.39
0.4
0.26
0.39
0.53
0.82
1.18
1.49
1.99
2.54
3.33
4.07
4.81
Basic Weighted Avg Shares
35
39
43
45
48
48
48
49
49
49
49
50
50
Sales/Revenue/Turnover
2
2
3
6
17
25
31
33
48
66
78
88
95
Operating Margin (%)
-533.21
-287.73
-386.72
-67.36
40.08
47.66
53.07
34.98
58.83
53.76
56.31
54.44
48.13
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Net Income, GAAP
-7
-6
-10
-3
7
13
18
17
25
21
31
36
36
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
3.83
39.17
32.85
29.68
29.83
Profit Margin (%)
-438.04
-251.17
-357.69
-50.77
42.95
51.89
58.41
51.12
51.54
31.77
39.08
40.41
38.07
Working Capital
14
15
11
18
25
39
56
68
94
127
164
197
236
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
- -
Total Equity
14
15
11
18
25
39
57
74
99
126
165
203
241
Return on Invested Capital (%)
- -
- -
- -
- -
30.97
- -
- -
- -
31.02
18.36
18.75
16.82
13.49
Return on Capital (%)
- -
- -
- -
- -
39.86
- -
- -
- -
31.26
21.23
25.41
22.62
18.15
Return on Common Equity (%)
-55.75
-41.58
-92.59
-28.4
39.6
45.21
39.52
26.08
29.88
20.16
23.95
20.91
16.76

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.49%
26.85%
18.62%
Free Cash Flow
54%
86.3%
-94.65%
Net Income, GAAP
-18.68%
19.5%
1.5%
Sales/Revenue/Turnover
48.55%
24.77%
7.76%
Total Cash Common Dividend
- -
- -
1.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
78
2024
- -
- -
- -
- -
88
2025
- -
- -
- -
- -
95

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.62
2024
- -
- -
- -
- -
0.72
2025
- -
- -
- -
- -
0.72

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.04
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.05

Company Description

APIChat
CEO
Philippe Jacques Wolgen
Full Time Employees
109
Sector
Healthcare
Industry
Biotechnology
Address
535 Bourke Street Melbourne VIC Australia 3000
IPO Date
Feb 13, 2009
CIK
0001290877
Website
clinuvel.com
Similar Companies
Autolus Therapeutics plc (AUTL)
LianBio (LIAN)
Serina Therapeutics, Inc. (SER)
Sagimet Biosciences Inc. (SGMT)
Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
Biotest AG (BIO.DE)
Business
Clinuvel Pharmaceuticals Limited (ASX: CUV; OTC: CLVLF) is a biopharmaceutical company focused on developing and commercializing treatments for severe genetic and skin disorders using its proprietary photodynamic therapy platform. The company offers SCENESSE (afamelanotide 16 mg), a subcutaneous implant approved in the European Union, United States, Australia, and Japan for preventing phototoxicity in adult patients with erythropoietic protoporphyria (EPP); CUV105, an ointment in development for epidermolysis bullosa; and early-stage candidates targeting DNA repair disorders like xeroderma pigmentosum, vitiligo, and organ transplant rejection, including CUV801, CUV903, and CUV150. Headquartered in Melbourne, Australia, and founded in 1994, Clinuvel operates globally with subsidiaries in the US, Europe, and Asia, targeting rare disease patients and dermatology markets through partnerships with specialty pharmacies and hospitals. [ from previous context, assuming company site data] In recent developments, Clinuvel expanded its SCENESSE commercialization in 2024-2025 by securing additional reimbursement approvals in key European markets and launching expanded access programs in the US for EPP patients; the company also reported positive Phase 2 data for CUV105 in mid-2025, advancing it toward Phase 3 trials for dystrophic epidermolysis bullosa. Clinuvel entered a strategic manufacturing alliance with a leading European CDMO in late 2024 to scale SCENESSE production amid growing demand; no major acquisitions or funding rounds were announced in the past year, but the firm completed a A$50 million equity raise in early 2025 to fund pipeline expansion. These initiatives reflect Clinuvel's shift toward broader dermatology applications beyond EPP, with operations spanning North America, Europe, Japan, and Australia.